Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: fewer (74), minus (30), excluding (249)

InP RCODOX M(66) cyclophosphamide doxorubicin methotrexate rituximab vincristine

Description: Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-DOXORUBICIN-METHOTREXATE-RITUXIMAB-VINCRIS
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/InP-RCODOX-M66-cyclophosphamide-doxorubicin-methotrexate-rituximab-vincristine.pdf

InP RCODOX M(65) cyclophosphamide doxorubicin methotrexate rituximab vincristine

Description: Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-DOXORUBICIN-METHOTREXATE-RITUXIMAB-VINCRIS
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/InP-RCODOX-M65-cyclophosphamide-doxorubicin-methotrexate-rituximab-vincristine.pdf

Ibrutinib (MCL) (560mg)

Description: Chemotherapy Protocol Mantle Cell Lymphoma Regimen Ibrutinib • MCL – Ibrutinib (560mg) Indication • Mantle Cell Lym
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Ibrutinib-MCL-560mg.pdf

FC PO (5 day)-Cyclophosphamide-Fludarabine PO 5 day Ver 1.1

Description: Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-FLUDARABINE ORAL 5 DAY (FC PO 5 day) Regimen Lymph
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/FC-PO-5-day-Cyclophosphamide-Fludarabine-PO-5-day-Ver-1.1.pdf

Cyclophosphamide-Etoposide PO Ver 1.1

Description: Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-ETOPOSIDE ORAL Regimen Lymphoma – Cyclophosphamide
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Cyclophosphamide-Etoposide-PO-Ver-1.1.pdf

Bexarotene

Description: Chemotherapy Protocol Cutaneous T-cell Lymphoma BEXAROTENE Regimen • Cutaneous T-cell Lymphoma - Bexarotene Indication • B
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Bexarotene.pdf

InPEtoposideIfosfamide(5dy)Ver1

Description: Chemotherapy Protocol SARCOMA ETOPOSIDE-IFOSFAMIDE (5 day) Inpatient Regimen Regimen Sarcoma-InP-Etoposide-Ifosfamide (5 day)
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Sarcoma/InPEtoposideIfosfamide5dyVer1.pdf

Binimetinib-Encorafenib

Description: Chemotherapy Protocol SKIN CANCER Binimetinib-Encorafenib Regimen • Skin – Binimetinib-Encorafenib Indication • Unresectable or metast
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Binimetinib-Encorafenib.pdf

Lenvatinib(60kg or greater)

Description: Chemotherapy Protocol HEPATOCELLULAR CANCER LENVATINIB (60kg or greater) Regimen • Hepatocellular – Lenvatinib Indication • Lenva
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Hepatobiliary/Lenvatinib-60kg-or-greater-Ver1.pdf

NilotinibChronic

Description: Chemotherapy Protocol Chronic Myeloid Leukaemia Nilotinib (chronic phase) Regimen • CML – Nilotinib (chronic phase)
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CML/NilotinibChronic.pdf

261 to 270 of 1000

Previous … 25 26 27 28 29 … Next